Business Association: PFD Capital Partners

PFD Annouces Completion of the First-in-Human iKnee Implantation

PFD Capital Partners, Inc. announced the successful completion of the first-in-human implantation of the investigational iKnee on July 31, 2026, at Prime Surgical Center of Newport Beach, marking the start of the device’s human clinical evaluation. The patient-specific implant, developed by PFD iOrthopedics from Robert Thomas Grotz, MD’s patented Resilient Arthroplasty Device (RAD) technology, is […]

PFD Announces July 31 First-in-Human Implantation of the iKnee

PFD Capital Partners announced the scheduled July 31, 2026, first-in-human implantation of the investigational iKnee at Prime Surgical Center of Newport Beach. The outpatient procedure will be performed by principal investigator Dr. Christopher Woodson, with PFD Director of Clinical Operations Eric Hansen serving as the first patient. The milestone begins the iKnee’s human clinical evaluation […]

PFD Highlights Dr. Daniel Rastein’s Invitation to Participate in FDA Patient-Focused Drug Development Meeting on Nonhealing Chronic Wounds

PFD Capital Partners announced that Dr. Daniel Rastein, Founder and CEO of CassdermaRx, has been invited to participate in the FDA’s upcoming Patient-Focused Drug Development public meeting on nonhealing chronic wounds. The meeting is intended to gather patient and caregiver perspectives on the real-world burden of chronic wounds, current treatment challenges, meaningful outcomes, and clinical […]

PFD Announces Regeneration Biomedical’s FDA Fast Track Designation and Phase IIa Trial Site Selections

PFD Capital Partners announced that Regeneration Biomedical, Inc. received FDA Fast Track designation for RB-ADSC, its investigational autologous adipose-derived stem cell therapy for mild to moderate Alzheimer’s disease, and selected multiple Phase IIa clinical trial sites to support a larger randomized, placebo-controlled evaluation of the treatment. The release explains that RB-ADSC uses Wnt-activated adipose-derived stem […]

PFD Capital Partners Announces Closing of PFDSelect Medical Receivables 1018, LLC

PFD Capital Partners announced the closing of PFDSelect Medical Receivables 1018, LLC, the 17th special purpose entity in PFD’s 1000 Series focused on Personal Injury Medical Accounts Receivable financing. PFDSMR1018 launched on March 11, 2026, and closed to new investments on May 18, 2026, with participation from 99 investors, including 75 new investors, 34 referral-based […]

PFD Provides Update On IRA K-1s And UBIT

PFD Capital Partners is addressing recent IRA custodian notices regarding Schedule K-1 reporting and potential UBTI, clarifying that these are routine, non-specific communications sent broadly to IRA holders. Based on guidance from legal counsel and independent CPAs, PFD believes that income generated through its structure qualifies as qualified business income (QBI) and not unrelated business […]

PFD Provides Update On 2025 Schedule K-1 Reporting

PFD Provides Update On 2025 Schedule K-1 Reporting PFD Capital Partners provided an update on the status of its 2025 Schedule K-1 reports, noting that its independent accounting firms, Holthouse, Carlin & Van Trigt LLP (HCVT) and Bud Weythman, CPA, are finalizing year-end audits and preparing the forms, with completion expected on schedule. A majority […]

PFD Announces Launch Of Three New Special Purpose Entities

PFD Capital Partners announced the launch of three new 2026 Special Purpose Entities—PFDSMR1017, PFDSMR2002, and PFDSMH3002—further expanding its medical accounts receivable specialty finance platform, including both personal injury–based receivables and a hybrid medical technology investment offering. These new offerings reflect PFD’s continued growth, disciplined underwriting approach, and commitment to building long-term relationships with medical providers […]

PFD Announces The U.S., Patent Office Has Granted Regeneration Biomedical, Inc. A New Patent For Its CEREWiNT™ Technology Platform

Irvine, CA. March 17, 2026 — PFD Capital Partners, Inc. (PFD) today announced that Regeneration Biomedical, Inc. (RBI) has been awarded U.S. Patent No. 12,529,034 B2, titled “WNT-Activated Adipose-Derived Stem Cell Apparatus, Methods and Systems.” The newly granted patent significantly expands RBI’s intellectual property portfolio and further positions the company at the forefront of regenerative […]